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The prevalence of vitamin D inadequacy and breast cancer are both high among women liv-
ing in Karachi, Pakistan.
Methods
A matched case control study was conducted in two hospitals of Karachi, Pakistan to evalu-
ate the association of vitamin D (serum 25-hydroxyvitamin D) concentrations, vitamin D sup-
plementation and sun exposure with breast cancer among Pakistani women. A total of 411
newly diagnosed histologically confirmed primary breast cancer cases were enrolled and
784 controls, free of breast and any other cancers, were matched by age (year of birth ± 5
years), residence in the same geographic area and study site. Information was collected on
sociodemographic history, history of vitamin D supplementation, past medical and obstetri-
cal history, family history of breast cancer, sun exposure history, histopathology reports and
anthropometric measurement and venous blood was collected to measure serum 25-hydro-
xyvitamin D (25(OH)D) concentration.
Results
Compared to patients with sufficient serum vitamin D (>30 ng/ml), women with serum vita-
min D deficiency (<20ng/ml), had a higher risk of breast cancer (OR = 1.65, 95%CI: 1.10,
2.50). Women with history of vitamin D supplementation one year prior to enrollment, had
significant protective effect against breast cancer (OR = 0.32, 95% CI: 0.24, 0.43).
Conclusions and recommendation
Serum vitamin D deficiency was associated with increased risk of breast cancer, while vita-
min D supplementation was associated with decreased risk of breast cancer. In Pakistani
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women, where vitamin D deficiency is common, raising and maintaining serum vitamin D at
population level is a safe and affordable strategy. It may play a role in reducing the incidence
of both vitamin D deficiency and breast cancer, particularly among poor women where the
breast cancer mortality is highest due to limited resources for early detection, diagnosis, and
treatment. The effects of vitamin D with regard to breast cancer risk in Karachi Pakistan
should be further evaluated.
Background
Cancer rates and the financial burdens of cancer treatments are increasing worldwide in both
developed and developing countries [1, 2]. In developing countries, where health systems are
not sufficiently well resourced to provide the optimum facilities for cancer diagnosis and can-
cer management, cancer is particularly associated with high morbidity and mortality [3].
Expensive targeted cancer treatments continue to advance the treatment for breast cancer in
more affluent countries. However, in developing economies, like Pakistan, the exploration of
more affordable cancer prevention, and management is a necessity but currently there is lim-
ited cancer prevention research and available strategies [4].
There is substantial evidence supporting the theory that hormonal mechanisms play a vital
role in the etiology of breast cancer. Epidemiological studies and laboratory findings indicate
that vitamin D has potential anticancer activity [5]. An individual’s serum 25(OH)D concen-
trations are principally determined by the amount of the skin’s ultraviolet (UVB) radiation
exposure from the sun and this can also be influenced by skin pigmentation. In addition, there
are dietary sources of vitamin D, particularly oily fish, and easily affordable and accessible vita-
min D supplements. In a meta-analyses of observational studies and randomized controlled
trials by Theodoratou, et al, out of 137 diseases linked with vitamin D deficiency (including
cardiovascular, autoimmune, infectious, skeletal, malignant, metabolic, and other diseases),
ten outcomes were studied and results showed an association of vitamin D deficiency (VDD)
with birth weight, childhood dental caries, and parathyroid hormone concentrations in
patients suffering from chronic kidney disease [6]. In other studies, low 25(OH)D concentra-
tion (<20ng/ml) was associated with multiple types of adverse musculoskeletal diseases and
non-musculoskeletal health problems, for example cardiovascular diseases [7], hypertension,
type 2 diabetes mellitus [8] and cancers, osteomalacia, rickets, hypophosphatemia, osteoporo-
sis, autoimmune diseases (e.g. psoriasis) and infectious diseases [9], and therefore, there are
national programs that vary among countries to provide dietary vitamin D fortified foods [10].
It has also been well established that low concentrations of 25 (OH)D are associated with an
increased risk of some cancers, for example colorectal cancer [11, 12]. In a recent meta-analy-
sis, it was found that there was a highly significant dose-response relationship between serum
25(OH)D concentrations and overall survival in breast cancer patients [13].
Despite the biological plausibility that vitamin D has an anticancer role, the literature on
the relationship between breast cancer and 25(OH)D concentrations remains more controver-
sial. The research findings evaluating the role of vitamin D as a possible preventive agent
against breast cancer vary, and the optimal serum 25(OH)D concentration for cancer and
other diseases prevention is still unknown [14]. Overall, the results from a number of cell line
experiments, mouse studies, ecological studies, observational studies and some clinical trials
indicate that vitamin D has anticancer activity [15].
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Ecological studies on large population living in diverse countries including Europe, China,
Australia, France Japan and the USA have also consistently shown the protective association of
increased UVB sun exposure and latitude on reducing breast cancer incidence and mortality
[16–19]. However, ecologic fallacy and lack of data relating to serum 25(OH)D concentrations
at an individual level are major weaknesses of such studies.
Results from observational studies show a protective association of increased 25(OH)D
concentrations against breast cancer which is observed more frequently in case control studies
than in cohort studies [20–26]. Prospective studies investigating the role of vitamin D in breast
cancer have mixed results [27–31] with some studies showing no association with breast can-
cer [31–37]. A case–control study nested within the Nurses’ Health Study II (NHSII) did not
show any association of breast cancer with vitamin D [30]. In addition, in a cohort study from
1965–1976, it was found that there was no difference in the pre diagnostic concentrations of
1,25(OH)2D between cases of breast cancer and their matched control subjects [29]. These
inconsistent results of association of serum vitamin D with breast cancer can be due to multi-
ple factors like different population, and tumor biology. One problem with cohort studies is
that there is sometimes a long period of time between the blood draw for vitamin D and the
outcome observed. That long-time gap may explain some of the discrepancy between the find-
ings of case-control studies and cohort studies.
There is dearth of well-designed and conducted large randomized controlled trials (RCTs)
to assess if vitamin D supplementation can increase serum 25(OH)D concentrations and
reduce the incidence of breast cancer. Results vary, with some clinical trials supporting the
results of association studies [38, 39], while others showing an absence of cancer prevention by
vitamin D [40]. Some of the limitations of RCTs done are inadequate sample sizes and limited
time of follow-up. There have been several meta-analyses of case-control studies that demon-
strate an association of high serum 25(OH)D with lower incidence of breast cancer [41–44]. A
meta-analysis of prospective studies showed a 12% protective association of serum 25(OH)D
of 27-<35 ng/mL with breast cancer, but there was no more protective effects above 35 ng/ml
in a dose-response analysis [45]. In another meta-analysis by Hong et al, a serum concentra-
tion of greater than 30 ng/ml of serum 25(OH)D was associated with decreased risk of breast
cancer [46]. The protective association has also been observed in postmenopausal but not in
premenopausal women in another meta-analysis by Stearns V et al. [47]. A meta-analysis of 14
studies carried out by Wang et al, that included 9110 breast cancer cases and 16,244 controls
showed an overall protective effect of high serum 25(OH)D on breast cancer risk (RR = 0.84,
95% CI = 0.750–0.951) [48] with a 3.2% reduction of breast cancer risk with every 10 ng/ml
increase in serum 25(OH)D concentrations (p<0.001) in postmenopausal women only [48].
However, there was no protective effect of 25(OH)D on breast cancer risk among premeno-
pausal women [48]. Similarly, a meta- analysis of 6 studies suggested that higher intakes of
vitamin D were associated with a lower risk of breast cancer [49]. A recent review based on
cohort studies only did not find any association of vitamin D with breast cancer but it excluded
consideration of cross-sectional, case control studies and ecological studies [50]. On the con-
trary, in two cohort studies: ESTHER (Germany) and TROMSO (Norway); and a subset
nested-case control study from EPIC-Elderly (Greece, Denmark, Netherlands, Spain and Swe-
den) consisting of a total of 15,486 individuals, there was some evidence of increased breast
cancer with higher pre-diagnostic 25(OH)D concentrations [51]. Overall the meta-analyses do
provide evidence of a chemo-preventive role of vitamin D against breast cancer but there is a
need of further randomized control trials, particularly in populations with extremes of serum
25(OH)D concentrations.
Studies in Asian population of breast cancer and the possible relationship with 25(OH)D
concentrations, are limited [52–54]. A study from Jordon, although with limited number of
Vitamin D and breast cancer
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women, did show an association of breast cancer with VDD [55]. Results from a case-control
study in Iran also support the protective effect of higher serum concentration of 25(OH)D
against breast cancer [56]. Another case control study in Asian women also suggests potential
preventive effect of vitamin D on breast cancer for Korean women [57]. Similar findings of
protective role of vitamin D against breast cancer are reported from studies in Indian popula-
tions [52, 58]. Two studies done in Pakistan have only descriptive analysis in one [59] and
small sample size in the other study [60].
Since Pakistani population was reported to have low concentrations of serum 25(OH)D
[61] and high rates of breast cancer [62], we conducted a case control study in this population
examining the association between women’s serum 25(OH)D concentrations and breast can-
cer risk. In addition, the major sources of vitamin D, endogenous cutaneous synthesis through
UVB sun exposure and exogenous through intake of vitamin D supplements, were evaluated
in this population. Serum 25(OH)D concentrations of women were determined since this is
the best biomarker to measure vitamin D status [63].
Methods
Study design and setting
This matched case control study was conducted in Karachi, the 5th most populous city in the
world with an estimated population of 24 million in 2017. Study participants were sourced
from Aga Khan University Hospital (AKUH), which is a private JCIA accredited academic
medical center, and the Karachi Institute of Radiation and Nuclear Medicine Hospital
(KIRAN) which is a leading referral and cancer treatment public hospital and provides finan-
cial assistance for diagnosis and treatment on welfare basis, to more than 75% of its patients,
who come from all over Pakistan.
Study participants
All women who were newly diagnosed with a primary histologically confirmed case of breast
cancer between February 2015 to July 2018 were eligible as cases. Women who were extremely
sick, unable to complete the interview, been living outside Pakistan for more than a year and
diagnosis of breast cancer for greater than 6 months before study enrolment were excluded.
Women receiving adjuvant or neoadjuvant chemotherapy or radiation, with diagnosis of non-
epithelial breast tumor (ICD-O histology code 8800), and women lost to follow up during
their metastatic and laboratory work up were also excluded from the study.
For each patient two controls free of any cancer diagnosis were matched by age (year of
birth ± 5 years), residence in the same geographic area and hospital. The control women were
recruited from those attending in- and out-patient services for general medical, and surgical
departments of the two participating hospitals and who had no previous diagnosis of breast
cancer or any other cancer. The controls enrolled from surgery were those who came for fol-
low up of mammography screening, with benign breast symptoms. Controls sourced from
general medicine clinics had a range of medical conditions, for example diabetes, hyperten-
sion, headaches and anxiety. All efforts were made to avoid selection bias by proper selection
of cases and controls and standardized, and uniform data collection procedures.
The number of enrolled cases and controls subjects was decided based on certain assump-
tions. We assumed the prevalence of deficiency of vitamin D and other risk factors amongst
the control group to be in the range of 10–90%. In an audit of blood samples at Aga Khan Uni-
versity, VDD noted was 66.1% [64]. In order to be able to detect an odds ratio of at least 2 with
a power of 80%, at a significance concentration of 5% and considering a 1: 2 ratio between
cases and controls, we calculated a sample size of 400 cases and 800 controls. However, in the
Vitamin D and breast cancer
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final achieved sample, a total of 411 breast cancer cases and 784 control subjects were enrolled
(55 stratas had 1:1 case control ratio).
Ethics approval and consent to participate
The ethical approval was obtained by the Human Research Ethics Committee of the University
of Adelaide and the Ethical Review Committees of two hospitals in Karachi Pakistan: Aga
Khan University Hospital AKUH & Karachi Institute of Radiation and Nuclear Medicine Hos-
pital KIRAN. Patients who were literate read and signed the informed consent form, and ver-
bal consent was obtained from those who could not read or write.
The pilot study and pretesting
In the first phase, a pilot study was undertaken to pretest the complete questionnaire on a sam-
ple of 50 patients attending the outpatient department of Jinah Postgraduate Medical Center
JPMC and AKUH between Aug 2014-Jan 2015. Those subjects were not included in the main
study. The questionnaire was revised and finalized based on the pretest results, to ensure stan-
dardization and reliability of the questionnaire in urdu, the local language.
Questionnaire
All consenting participants were interviewed using the same structured questionnaire. The
questionnaire was divided into different sections of sociodemographic history, history of any
vitamin D supplementation, and past medical and obstetrical history, family history of breast
cancer or any other cancer, sun exposure history, histopathology reports and anthropometric
measurement. Where relevant, clinical notes and pathology reports were assessed. Socio
demographic factors included age, ethnicity, education, marital status, place and type of resi-
dence, number of dependants and current employment status. Education was treated as an
ordinal variable and categorized as<8, 8–12, or > 12 years of full-time study. Socio-economic
(SES) factors included education, place and type of residence, crowding index, home owner-
ship, number of rooms, total household members and total household monthly income.
Crowding index was also calculated as number of household members divided by number of
rooms and was further categorized as<1, 1–2,>2. Factor analysis was used to identify the
important variables for socioeconomic status and a composite variable was calculated for
socioeconomic status and categorized into upper, middle and poor.
Participants self-reported their family history of breast cancer as none (no first-degree fam-
ily history), or one first degree relative and age at diagnosis of breast cancer, or multiple
affected first-degree relatives or second-degree relatives and ages at breast cancer diagnosis.
Other variables assessed included reproductive history, body mass index (BMI), and history of
benign breast disease. Histopathology and estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor (HER2/ neu) status of breast cancer cases were
retrieved from medical records. Tumor characteristics relating to tumor size (T), nodes
involved (N), and presence of metastasis (M) were also extracted from pathology reports and
cancer staging expressed as stage I (the least advanced stage) to stage IV (the most advanced
stage).
The STROBE standardised reporting guidelines for case control studies were followed to
ensure standardised conduct and reporting of the study [65].
Measurement of serum 25(OH)D concentrations. For all enrolled subjects venous blood
samples (2.5 ml) were collected in yellow topped gel tubes. For breast cancer patients, collec-
tion was within 30 days of diagnosis of cancer and prior to chemotherapy, and from controls,
at the end of the questionnaire interview. The collected blood was transported on the same day
Vitamin D and breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0225402 January 22, 2020 5 / 21
to the Section of Clinical Chemistry, Department of Pathology & Laboratory Medicine, at
AKUH for biochemical analysis. Serum was separated by centrifugation and stored at -80˚C
until analysis. Serum 25(OH)D concentrations was measured by a kit from DiaMetra S.r.I.
Headquarter: Via Garibaldi, 18–20090 SEGRATE (MI) Italy, using solid phase enzyme-linked
immunoassay (ELISA) based on the principle of competitive binding. A dose response curve
was used to ascertain 25(OH)D concentrations range in unknown specimens by using five
human serum-based calibrators from C0 to C5 with concentration range from 0–120 ng/ml.
The lowest detectable concentration of 25(OH)D that can be distinguished from the calibrator
0 was 0.3 ng/ml at 95% confidence limit. The assay had intra assay variability and inter assay
variability of< 6.4% and<6.955 respectively. Five low and high vitamin D control samples
provided with the kit were run with each batch of samples analysed for quality control. The
AKUH laboratory participates in the College of American Pathologists CAP proficiency test-
ing. The cut-off used to define VDD is the point where parathyroid hormone (PTH) starts to
rise [66]. Vitamin D deficient status was defined as serum 25(OH)D concentration of 12–19
ng/ml, vitamin D insufficient as 20-30ng/ml and vitamin D sufficient as>30ng/ml.
Vitamin D supplements intake. The use of vitamin D supplement (both injections and
oral), was assessed in relation to the index year, defined as one year prior to breast cancer diag-
nosis for cases or the interview for controls. Vitamin D supplementation was assessed by ask-
ing participants if they had been taking vitamin D supplements regularly, occasionally or not
at all in their lifetime, with the mode of administration identified as either injections, oral tab-
lets or ampoules. Similar information was used to assess use of multivitamins, name of the
multivitamins, and vitamin D calcium combination supplementation with details about fre-
quency of intake and the brands of tablets (where available) were also determined.
Sun exposure measurement questionnaire. The geographic location of Karachi (latitude
24.51’N, longitude 67˚020E and elevation 8 metres) served as a surrogate measure for ultravio-
let B (UVB) exposure. It should be noted that the climate of Karachi provides ample sunlight
throughout the year for maintaining adequate 25(OH)D concentrations. To assess sun expo-
sure among cases and controls, the validated long-term sun exposure measurement question-
naire (LT SEM-Q) was used. This questionnaire has been validated against gold standard
ultraviolet (UV) dosimeters [67]. This questionnaire estimates retrospective sunlight exposure
throughout a patient’s lifetime, which is especially relevant for chronic diseases like breast can-
cer that develop over many years. The questionnaire assessed duration of sun exposure to vari-
ous parts of the body, skin tone of the individual, use of sunscreens and other cosmetics, and
sun avoidance behaviour. The time spent outdoors between 10 am and 4 pm in summers and
winters was assessed to estimate the amount of time in minutes per day and per week each par-
ticipant was exposed to UVB radiations. Other factors such as atmospheric pollution, latitude,
and season depend on the urban or rural setting and province of the enrolled subjects were
addressed by matching cases and controls on region of residence.
Skin tone of the participants was assessed against a shade card by matching shade of the
skin on the inner side of the forearm (unexposed part) of the participant and forehead
(exposed part) with the shade on the card, according to LT SEM-Q, to match the skin tones of
Asian population. Details of weights given to sun exposure variables are shown in S1 Table.
The final scoring algorithm of sun exposure score in summers and winters was created by mul-
tiplying the time (minutes) spent in the sun by the proportions of the different variables.
Statistical analysis
Conditional logistic regression with matched sets as strata was used to compute odds ratios
(ORs) and 95% confidence intervals (CIs) to evaluate the association of 25(OH)D, sun
Vitamin D and breast cancer
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exposure, and vitamin D supplements with breast cancer. We examined potential confounding
by the following covariates as categorical variables: socioeconomic status, education, parity,
body mass index (BMI), first-degree family history of breast cancer, breastfeeding, and meno-
pausal status. SPSS 22.0 software (IBM Statistics, Armonk, New York, USA) was used where a
p-value< 0.05 was accepted as significant for all statistical tests.
Results
Table 1 presents the median, minimum, maximum and mean with SD for continuous data of
serum 25(OH)D concentrations showing high prevalence of VDD among both cases and con-
trols. Individual 25(OH)D concentrations encompassed a broad range from highly deficient
(0.3 ng/ml) to exceptionally high (165.5 ng/ml). The median 25(OH)D concentrations among
breast cancer cases was lower (15.3 ng/ml) compared to controls (16.7 ng/ml).
To enable a more rigorous statistical analysis, cases and controls were categorized into four
different concentrations of 25(OH)D, defined as severely deficient (<12 ng/ml), deficient (12–
19 ng/ml), insufficient (20-30ng/ml) and sufficient (>30ng/ml) (Table 2). VDD was signifi-
cantly more frequent in breast cancer cases, with 38.9% of breast cancer cases categorized as
severe VDD compared to 32.9% of controls, while 28.8% of breast cancer cases were classified
as deficient compared to 23.8% of controls. Vitamin D sufficiency was higher among controls
(24.8%) compared to cases (17.4%).
Overall 60.2% of women in Karachi had serum concentrations of 25(OH)D < 20ng/ml,
which is considered to indicate vitamin D deficiency. A severe deficiency of serum 25(OH)D
<12 ng/ml was reported among 34.8% of women.
Table 3 presents the demographic and reproductive characteristics of all the study partici-
pants stratified according to serum 25(OH)D concentrations, compared by chi-square tests.
Note the severely deficient and deficient 25(OH)D categories were combined in this and sub-
sequent analyses. Vitamin D deficient women, compared with vitamin D sufficient women,
were significantly more likely to be in the 35-44-year age group, premenopausal, and of lower
SES.
Those women with VDD and insufficiency on average had higher parity. This is also likely
to be related to their lower SES status.
Table 1. Serum concentration of vitamin D among cases and controls.
Serum vitamin D (ng/ml) Median (SD) Minimum Maximum Mean SD
Cases 15.3 (15.6) 0.3 165.5 20.1 21.3
Controls 16.7 (20.1) 0.9 149.0 23.0 20.3
https://doi.org/10.1371/journal.pone.0225402.t001
Table 2. Number and percentage of breast cancer cases and controls for different serum 25(OH)D
concentrations.
Serum 25(OH)D (ng/ml) Case Control All participants p value�
n % n % n %
0.02
Severely deficient <12 112 38.9 202 32.9 314 34.8
Deficient 12–19 83 28.8 146 23.8 229 25.4
Insufficient 20–30 43 14.9 114 18.6 157 17.4
Sufficient >30 50 17.4 152 24.8 202 22.4
�p values generated from Chi-square or Fisher Exact test
https://doi.org/10.1371/journal.pone.0225402.t002
Vitamin D and breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0225402 January 22, 2020 7 / 21
Table 4 presents the distribution of tumor characteristics within the three different serum
25(OH)D concentrations. There was no significant association of 25(OH)D concentrations
with any of these tumor characteristics.
The use of different forms of vitamin D and multivitamin supplementation was assessed
among cases and controls. For each form of supplementation, the breast cancer group had a
significantly lower usage than the control group (Table 5).
There was a significant association between serum 25(OH)D concentrations and intake of
vitamin D supplements with 72% of breast cancer cases in the VDD group being non-users of
Table 3. Sociodemographic, reproductive and anthropometric characteristics of women stratified according to
serum 25(OH)D concentrations.








n = 543 n = 157 n = 202
n % n % n %
Age groups (years) <0.001
<35 100 18.4 19 12.1 22 10.9
35–45 209 38.5 55 35.0 54 26.7
46–54 128 23.6 36 22.9 52 25.7
55 & above 106 19.5 47 29.9 74 36.6
Education 0.57
<grade 8 140 25.8 31 19.7 49 24.3
grades 8–12 178 32.8 56 35.7 63 31.2
>grade 12 224 41.3 70 44.6 90 44.6
Socioeconomic status (SES) 0.002
upper 62 11.4 34 21.7 35 17.3
middle 308 56.7 84 53.5 122 60.4
lower 173 31.9 39 24.8 45 22.3
Parity 0.02
nullipara 85 15.7 14 8.9 30 14.9
�3 232 42.7 85 54.1 105 52.0
>3 226 41.6 58 36.9 67 33.1
Breastfeeding 0.11
no 12 2.6 9 6.3 7 4.1
yes 443 97.4 133 93.7 164 95.9
Menopause <0.001
menopause 247 45.7 83 53.2 123 61.8
pre menopause 293 54.3 73 46.8 76 38.2
Family history of breast cancer 0.46
yes 123 22.7 40 25.5 54 26.7
no 420 77.3 117 74.5 148 73.3
Body mass index�� 0.66
<23 83 16.3 21 14.4 39 20.0
23–25 71 14.0 23 15.8 25 12.8
>26 354 69.7 102 69.9 131 67.2
�p values generated from Chi-square or Fisher Exact test,
��Weight (kg)/height (m)2
https://doi.org/10.1371/journal.pone.0225402.t003
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vitamin D supplementation compared to 50.6% of controls. Vitamin D users had higher
serum vitamin D sufficiency among both cases and controls (S2 Table).
There was no difference in the total sun exposure score between cases and controls and
therefore no association with breast cancer risk (Table 6). However, when component vari-
ables of sun exposure score were analyzed separately, women with more sun avoidance behav-
ior and an attire covering their head, neck, full legs and full arms had an increased risk of
breast cancer. This was also associated with increased VDD (data not shown). Further detail of
distribution of sun exposure score and its component variables among breast cancer cases and
controls is presented in S3 Table.
Table 7 presents multivariable analysis showing that women with serum VDD (<20ng/ml),
had a higher risk of breast cancer compared to patients with sufficient serum vitamin D (>30
ng/ml) (OR = 1.65, 95%CI: 1.10, 2.50). Women with a history of vitamin D supplementation
were significantly protected against breast cancer (OR = 0.32, 95% CI: 0.24, 0.43). Women
wearing the chadder and/or burqa resulting in minimal exposure to sunlight had a higher
breast cancer rate compared to women without those attires (OR = 1.80, 95% CI: 1.25, 2.59)
and (OR = 1.50, 95% CI: 1.05, 2.16) respectively.
Discussion
In this study, unique data for each woman for assessment of all sources of vitamin D, including
sunlight exposure and various types of vitamin D supplementation, and their serum
Table 4. Association between serum 25(OH)D concentrations(ng/ml) and the tumor characteristics among breast
cancer cases.
Variable category Deficient (<20) Insufficient (20–
30)
Sufficient (>30) p value�
n % n % n %
Histopathology IDC 160 85.6 36 87.8 40 80.0 0.39
lobular 7 3.7 1 2.4 5 10.0
Others 20 10.7 4 9.8 5 10.0
ER positive 111 67.7 19 63.3 32 74.4 0.57
negative 53 32.3 11 36.7 11 25.6
PR positive 98 59.8 15 50.0 32 74.4 0.09
negative 66 40.2 15 50.0 11 25.6
Grade of tumor III 74 41.6 13 35.1 11 23.9 0.08
I/II 104 58.4 24 64.9 35 76.1
Tumor size �5cm 98 55.4 20 57.1 24 55.8 0.98
>5cm 79 44.6 15 42.9 19 44.2
Nodes NoN1 121 72.9 29 82.9 29 69.0 0.37
N2 30 18.1 2 5.7 7 16.7
N3 15 9.0 4 11.4 6 14.3
Metastasis no metastasis 130 81.8 24 80.0 31 81.6 0.97
metastasis 29 18.2 6 20.0 7 18.4
TNM Stage Stage I 23 15.5 10 34.5 5 13.9 0.24
Stage II 53 35.8 8 27.6 11 30.6
Stage III 43 29.1 5 17.2 13 36.1
Stage IV 29 19.6 6 20.7 7 19.4
�p values generated from Chi-square or Fisher Exact test
Abbreviations ER Estrogen receptor PR progesterone receptor
https://doi.org/10.1371/journal.pone.0225402.t004
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Table 5. Association of different forms of vitamin D and multivitamin supplementation with breast cancer.
Vitamin D supplementation category Case (411) Control (784) OR 95% CI p value�
n % n %
Vitamin D tablets <0.001
Yes 27 6.7 154 19.6 0.28 (0.18–0.44)
No 375 93.3 630 80.4 Ref (1)
Oral vitamin D Drops <0.001
Yes 15 3.7 67 8.5 0.42 (0.23–0.75)
No 387 96.3 717 91.5 Ref (1)
Vitamin D calcium tablets <0.001
Yes 83 20.6 264 33.7 0.47 (0.35–0.64)
No 319 79.4 520 66.3 Ref (1)
Injection vitamin D <0.001
Yes 69 17.2 254 32.4 0.41(0.3–0.56)
No 333 82.8 530 67.6 Ref (1)
Multivitamin <0.001
Yes 100 24.9 300 38.3 0.52 (0.39–0.68)
No 302 75.1 484 61.7 Ref (1)
�p values generated from Chi-square or Fisher Exact test
OR = odds ratio, CI = confidence interval
https://doi.org/10.1371/journal.pone.0225402.t005
Table 6. Association of sun exposure variables including body parts exposed and sun avoidance behavior with breast cancer.
Variables case control OR (95% (CI) p value
n % n %
IA Total sun exposure score (mean SD) �
Score of Sun exposure in Summer per week 32.2 99.5 36.4 79.1 1.00 (1.01–1.02) 0.98
Score of Sun exposure in Winter per week 56.4 97.6 48.0 117.6 1.00 (0.99–1.00) 0.90
IB Individual components of sun exposure score
Head Covered yes 332 82.4 572 73.0 1.97 (1.41–2.74) <0.001
no 71 17.6 210 27.0 1 (Ref)
Face Covered yes 97 23.8 161 20.5 1.29 (0.94–1.76) 0.11
no 306 76.2 621 79.5 1 (Ref)
Neck Covered yes 255 63.3 426 54.5 1.53 (1.18–1.99) 0.001
no 148 36.7 356 45.5 1 (Ref)
Full Arm Covered yes 299 74.2 537 68.7 1.37 (1.03–1.82) 0.03
no 104 25.8 245 31.3 1 (Ref)
Hands Covered yes 11 2.7 14 1.8 1.78 (0.74–4.29) 0.19
no 392 97.3 768 98.2 1 (Ref)
Full Legs Covered yes 389 96.5 760 97.2 0.77 (0.35–1.66) 0.76
no 14 3.5 22 2.8 1 (Ref)
Sun avoidance behavior yes 361 89.6 660 84.4 1.73 (1.14–2.62) 0.01
no 42 10.4 122 15.6 1 (Ref)
Skin Tone Forehead (mean SD) � 5.7 1.5 5.3 1.4 1.19 (1.08–1.31) <0.001
attire outside chadder�� 146 36.3 214 27.4 2.28 (1.62–3.22) <0.001
burqa��� 177 44.0 320 41.0 1.89 (1.35–2.66)
other attires 79 19.7 247 31.6 1 (Ref)
�Mean SD
�� attire covering head, full arms and full legs
���attire covering head, face, neck, full arms and full legs
https://doi.org/10.1371/journal.pone.0225402.t006
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concentrations of 25 (OH) D was collected. The major finding was that lower serum 25(OH)D
concentration was significantly associated with an increased risk of breast cancer supporting
the hypothesis that vitamin D may play a protective role against breast cancer.
The median concentration of serum vitamin D in our study among cases was 15.3 (SD
15.6) ng/ml and among controls 16.7 (SD 20.1) ng/ ml. This was on average somewhat lower
than the median concentration of serum vitamin D (25(OH)D) of 18.8 ng/ ml reported in a
population based study of Pakistani population in Karachi in 2011 [61]. However, it is slightly
higher than the reported median serum 25(OH)D concentration of 13.5 ng/ml in a clinical lab-
oratory audit of Karachi Pakistan in the same year of 2011 [64]. In spite of the low latitude of
Karachi and regular monthly sunshine throughout the year, VDD was found in 60.2% of the
study participants with severe VDD (<12ng/ml) in 34.8%. of Pakistani women. Similar find-
ings were reported in neighboring countries of India and China with high prevalence of VDD.
In a study in Saudi Arabia, mean serum 25(OH)D concentrations were 13.1ng/ml [68]. This
compares to concentrations in the United States western population where VDD was reported
to be 28.9%. In the US study the incidence of VDD varied in different ethnic groups being
highest among blacks (82.1%), followed by Hispanics (69.2%). Being a Muslim community,
Pakistani women cover most of their body for cultural and religious reasons in a similar man-
ner to Arab women who also have reduced concentrations of vitamin D. However, 54.5% of
women in Singapore also had vitamin D deficiency, although they do not wear outer cloak and
scarf like Muslim women. This may suggest Asian women have a predisposition to low con-
centrations of vitamin D. Possible other factors reducing sun exposure include sun avoidance
behavior when outdoors, air pollution and dark skin pigmentation.
The study finding of association of lower serum 25(OH)D concentration with breast cancer
is consistent with the results of a prospective observational mediterranean study, where defi-
cient 25(OH)D concentrations were associated with node-positive high grade breast cancer
[69]. Another recent pooled cohort showed that serum 25(OH)D concentration > 60 ng/ml
lowered the risk of breast cancer by 80% compared to women with serum vitamin D <20ng/
ml [70]. A case control study in China and meta-analysis of 21 independent studies also sug-
gest that vitamin D may have a chemo-preventive effect against breast cancer [71]. A study
among Caucasian population in UK also reported that low concentrations of serum 25(OH)D
i.e. less than 20 ng/ml may increase risk of breast cancer [72]. However, in a Nurses’ Health
Study cohort, high concentrations of serum vitamin D was associated with non- significant
Table 7. Final multivariable adjusted ORs (95% CIs) of vitamin D with breast cancer among women in Karachi Pakistan (n = 1195).
Variable Category Crude OR (95% CI) Adjusted OR (95% CI)
Serum 25(OH)D concentration(ng/ml)
<20 1.83 (1.25–2.67) 1.65 (1.10–2.50)
20–30 1.56 (1.08–2.23) 1.17 (0.68–2.01)
>30 1 (Ref) 1 (Ref)
Use of vitamin D supplementation yes 0.28(0.18–0.44) 0.32 (0.24–0.43)
no 1 (Ref)
Attire outside chadder�� 2.28(1.62–3.22) 1.80 (1.25–2.59)
burqa��� 1.89(1.34–2.66) 1.50 (1.05–2.16)
other attires 1 (Ref) 1 (Ref)
Adjusted for socioeconomic status, education, parity, body mass index (BMI), first-degree family history of breast cancer, breastfeeding, and menopausal status.
�� covering head, full arms and full legs
���covering head, face, neck, full arms and full legs
https://doi.org/10.1371/journal.pone.0225402.t007
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reduced risk of breast cancer in older women [72]. A population-based case-control study
among premenopausal women of 289 cases and 595 matched controls, showed a significant
inverse association between breast cancer risk and serum 25(OH)D. Compared with <30
nmol/L of vitamin D the ORs (95% CI) for the upper categories of 30–45, 45–60,�60 nmol/L
were 0.68 (0.43–1.07), 0.59 (0.37–0.94) and 0.45 (0.29–0.70), respectively [73]. In a recent
study among Spanish women, there were decreasing ORs of breast cancer with increasing con-
centration of serum vitamin D (OR per 10nmol/L = 0.88; 95%CI = 0.82–0.94) [74]. In a study
of Indian women, low serum 25(OH)D concentrations (<20ng/ml) were associated with an
increased risk of breast cancer [75]. In a previously published smaller study of Pakistani
women, there was a similar association of VDD with increased risk of breast cancer [76]. Simi-
larly study findings by Kim Y et al showed association of high vitamin D status with low breast
cancer risk but strongly associated with better breast cancer survival [77].
This study results also show the association of vitamin D supplementation with both
increased serum concentrations of vitamin D and significantly decreased breast cancer risk. A
French Cohort study showed that current use (not past use) of calcium and Vitamin D supple-
ments was associated with a lower risk of developing breast cancer in postmenopausal women,
but not in pre-menopausal [78]. In a population-based case-control study, vitamin D supple-
ment intake > 400 IU/d compared with no supplement intake was found to be independently
associated with 24% reduced breast cancer risk (OR = 0.76, 95% CI = 0.59–0.98) while another
5 year follow up Sister Study of 50,884 participants showed that 25(OH)D concentrations were
associated with a 21% reduced hazard of breast cancer and 11% reduced hazard of breast can-
cer with self-reported vitamin D supplementation [79, 80]. The Iowa Women’s Health Study
has reported a small decrease in risk of breast cancer with vitamin D intake of>800 IU/d
among postmenopausal women only. The protective effect of Vitamin D was highest in the
first 5 years after baseline assessment of total intake but this protective effect decreased over
time [81]. Three other case control studies by Rollison et al, Rossi et al and Crew et al also sup-
ported the protective effects of vitamin D supplements [82–84]. However, some studies dem-
onstrate no protective association between vitamin D status and breast cancer risk and the
association remains unclear [85].
Another cohort study showed that vitamin D was associated with lower incidence of cardio-
vascular disease, respiratory disease, and fractures but not total incident cancers [86].
According to a review by Feldman et al, in spite of inconsistent epidemiological and clinical
trials results, some clinical studies agree with the beneficial effect of vitamin D in preventing
cancer and that correcting VDD and usage of vitamin D supplements might have a role to
reduce cancer incidence and improve cancer prognosis and outcome [87].
Vitamin D has been reported to have anticarcinogenic properties by stimulating apoptosis,
inhibiting and slowing cell growth factors and improving cell cycle regulatory factors [88].
Further, 1,25(OH)2D may inhibit angiogenesis and down-regulate estrogen receptors [89].
Activated Vitamin D may exert its antitumor effects through the vitamin D receptor (VDR)
that can modify the expression of target genes such as c-fos, p21, p27, and c-myc [90]. Another
biological plausible mechanism of vitamin D is through its important role in both innate and
adaptive immune system [91, 92]. Vitamin D functions as a transcription factor through the
VDR, and has been shown to play an important role in mammary gland development and
function, and is shown to be necessary and sufficient for tumor suppression in in vitro experi-
ments and in vivo models of mammary tumor cells extracted from mice [93, 94]. Also a review
suggests activation or restoration of the vitamin D regulated pathways has a potential to serve
as avenue for human breast cancer prevention [88].
In this study, there was no association of total sun exposure score (a proxy measure of 25
(OH)D concentrations) with serum 25(OH)D concentrations or breast cancer risk. This is
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contrary to those studies, particularly conducted at higher latitudes, which have shown a
strong positive association between sunlight exposure concentrations and 25(OH)D concen-
trations and negative association with various cancers including breast [17]. Similarly, among
a white population living in low latitude regions a multi-ethnic cohort nested case-control
study, showed high concentrations of 25(OH)D were associated with a reduced risk of post-
menopausal breast cancer. In a study of data from the Ontario Cancer registry, breast cancer
risks were reduced among women who had increasing sun exposure at earlier life (ages 10–19
years) These studies emphasize the importance of natural sources of vitamin D though sun
exposure. The absence of an association between total sun exposure score and vitamin D and
breast cancer in our study could also be due to inaccuracies in the collection of this type of
data, in particular the recall of past sun exposure time. Serum 25(OH)D is a useful biomarker
for measuring an individual’s recent exposure to sun exposure but may not correlate with life-
time sun exposure in different seasons. Moreover, it should be noted that Karachi is the fourth
most polluted city in the world with the presence of heavy smog and air pollution associated
with rapid industrialization. This further has the potential to affect access to sun exposure and
its UV-B light, causing decreased penetration of ultraviolet B radiation from the sun [95–97].
This study showed that there was no association of vitamin D with tumor characteristics,
ER or PR status or stage of breast cancer which is consistent with similar findings in a Chinese
population [98]. It is in contrast with research finding of an association of high 25(OH)D con-
centrations with lower tumor size at early breast cancer diagnosis [99] or ER/PR status of
tumor [100].
Some limitations of the study are to be noted. First, measurement of serum 25(OH)D con-
centrations was done by a single venous blood sample collected at one point in time which
may not be necessarily associated with 25(OH)D concentrations at the time of breast cancer
initiation or progression. However, findings from an important clinical trial suggest that
serum 25(OH)D concentration at a single time point may be representative of long-term vita-
min D status over a five-year period [70]. Another study showed that the correlation coeffi-
cient for measurement of serum 25(OH)D concentrations in samples collected in 1994 and
2008 ranged from 0.42 to 0.52, and was 0.80 when measured a year apart [101]. Therefore, sin-
gle measurement of serum 25(OH)D was based on the findings that an individual’s serum 25
(OH)D concentration remain relatively stable over time [102]. Moreover, this type of misclas-
sification would be non-differential to both cases and controls. Second, bias of reverse causa-
tion is inherent in case control studies, for example, due to the timing of blood collection for
assay of 25(OH)D concentrations after breast cancer diagnosis, the presence of breast cancer
cells and catalytic enzymes may affect the assays. Survival studies show that breast cancer itself
can cause lower serum concentrations of 25(OH)D [103] but in this study only newly diag-
nosed incident cases of breast cancer were enrolled. Even though participants were newly diag-
nosed with breast cancer in the study, they may very well have had the disease for quite some
time, since national breast cancer screening is not available in Pakistan and awareness about
symptoms of breast cancer is low. Third, it was a hospital-based study with lack of generaliz-
ability and Berkson’s bias [104] make it difficult to generalize as people seen in any hospital-
based case-control study are different in their clinical states from general population. However,
all efforts were made done to avoid selection bias by proper selection of cases and controls
with precise case definition and exposure definition, selection of controls from general practice
(independent of the exposure status), and uniform data collection procedures. Lastly, 1,25
(OH)2D concentrations may be more relevant due to the enzymatic conversion of 25(OH)D to
1,25(OH)2D, but it was not available in our study. Despite some limitations, the strengths of
this study are considerable, including a large sample size with good statistical power, a high
response rate and good participation in both cases and controls, best methods of measurement
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of all the variables using validated questionnaires and excellent laboratory methods for ELISA
assay, standardized, sample storage at -80C, blind assessment of laboratory personal testing for
25 OH(D), which ensured comparability of information in both cases and controls, were the
strengths of this study. Lastly, measurement of vitamin D from all sources was assessed espe-
cially serum concentration of 25(OH)D measurement was carried out which is the gold stan-
dard for assessing vitamin D status reflecting integration of cutaneous synthesis, as well as
dietary and supplemental vitamin D intake.
Overall this study suggests that there may be a potential role of cost- effective vitamin D in
reducing breast cancer incidence in a developing and limited resources country like Pakistan,
in contrast to more affluent societies. Pakistan has overburdened cancer care services in the
health and development systems with an inefficient palliative care which largely remains
unknown and neglected area. Cancer treatment facilities are situated in big cities and are
beyond the reach of the majority of the population. Pakistan’s ratio of health services to popu-
lation is one of the highest (1:90 million) [105].
Conclusion
To conclude, in this study, we observed that lower serum 25(OH)D concentration was associ-
ated with a higher risk of breast cancer supporting the hypothesis that deficient concentrations
of serum vitamin D may contribute to the process of carcinogenesis and its correction may
play a role in protection against breast cancer. VDD may be a modifiable risk factor for breast
cancer and restoring adequate concentrations of vitamin D may be a safe and affordable
approach that could reduce the incidence of VDD and breast cancer. This finding is also sup-
ported by the results showing that vitamin D supplementation in Pakistani women was associ-
ated with both increased concentrations of vitamin D and reduced incidence of breast cancer.
However, further studies, for example a prospective cohort study to confirm our findings in a
large prospective study for temporality, or large randomized clinical trials, are needed to draw
firmer conclusions and clarify this association in a dose-response relationship. Such large
RCTs may confirm the optimal concentrations of serum 25(OH)D for breast cancer preven-
tion, which may be effective and low-cost strategy for women to reduce their risk of breast can-
cer through preventing VDD and insufficiency.
In Pakistani women raising and maintaining serum 25(OH)D concentration at the popula-
tion concentration can be achieved through public awareness campaigns to improve 25(OH)D
concentrations through lifestyle changes that promote sensible sun exposure, consumption of
foods that contain vitamin D and are fortified with vitamin D, and use of vitamin D
supplements.
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